Novel regenerative therapy eases diabetes symptoms in mice

December 30, 2014

New research from Dr. Michael Rudnicki’s group is providing hope that r¬egenerative medicine could one day be harnessed to improve treatment for diabetes. Diabetes occurs when the body fails to properly regulate the level of sugar in the blood, either because the pancreas does not produce enough insulin, or because the body does not respond properly to insulin. This new research, led by postdoctoral fellow Dr. Jonathan Smid, shows that a protein called periostin plays a crucial role in pancreas regeneration in the mouse, and a synthetic version of this protein can stimulate pancreas regeneration and improve blood sugar regulation in a mouse model of diabetes. See Endocrinology for details. Dr. Rudnicki and his team are working with Fate Therapeutics to commercialize this technology and eventually bring it to patients.

Funder(s): JDRF, Stem Cell Network, Ontario Ministry of Research and Innovation, Canada Research Chairs Program, The Ottawa Hospital Foundation

Ottawa Hospital Research Institute

The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with its faculties of Medicine and Health Sciences. The Ottawa Hospital Research Institute includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. Support our research. Give to the Tender Loving Research campaign.

For further information, please contact

Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
Office: 613-737-8899 x73687
Cell: 613-323-5680